Class I phosphoinositide 3-kinase contains four isoforms of the catalytic subunit, p110␣, -␤, -␥, and -␦. At physiological levels of expression, the wild-type p110␣ isoform lacks oncogenic potential, but gain-of-function mutations and overexpression of p110␣ are correlated with oncogenicity. The p110␤, -␥, and -␦ isoforms induce transformation of cultured cells as wild-type proteins. This oncogenic potential requires kinase activity and can be suppressed by the target of rapamycin inhibitor rapamycin. The p110␦ isoform constitutively activates the Akt signaling pathway; p110␥ activates Akt only in the presence of serum. The isoforms differ in their requirements for upstream signaling. The transforming activity of the p110␥ isoform depends on rat sarcoma viral oncogene homolog (Ras) binding; preliminary data suggest the same for p110␤ and indicate Ras-independent oncogenic potential of p110␦. The surprising oncogenic potential of the wild-type non-␣ isoforms of class I phosphoinositide 3-kinase may explain the dearth of cancerspecific mutations in these proteins, because these non-␣ isoforms could contribute to the oncogenic phenotype of the cell by differential expression.
C
lass I of the phosphoinositide 3-kinases (PI3K) encompasses four isoforms of the catalytic subunit, known as p110␣, -␤, -␥, and -␦. All four share a basic domain structure with binding sites for the regulatory subunit and for Ras (rat sarcoma viral oncogene homolog) in the N-terminal portion of the protein, a C2 and a helical domain occupying the center region and the kinase domain making up the C-terminal portion of the molecule (1, 2) . Evidence is accumulating that the four p110 class I PI3K isoforms have distinct and specific functions. Although the ␣ and ␤ isoforms have a broad tissue distribution, expression of the ␥ and ␦ isoform is more restricted and predominantly detected in leukocytes (3) (4) (5) . Knockout experiments show that the ␣ and ␤ isoforms are essential for early embryonic development, whereas genetic inactivation of the ␥ or of the ␦ isoform allows normal development to adulthood but causes defects in the immune system (6) . The mode of regulation by upstream signaling also differs among the four p110 isoforms. Whereas the ␣ and ␦ isoforms are activated by signals from receptor tyrosine kinases, the ␥ isoform is linked to G protein-coupled receptors (2, 7, 8) . The ␤ isoform can accept input from both receptor tyrosine kinases and from G protein-coupled receptors (9) (10) (11) .
The oncogenic potential of p110␣ is well documented. p110␣ occurs as a retroviral oncoprotein, and gain of p110␣ function by mutation or overexpression is common in human cancers (12) (13) (14) (15) (16) . In contrast, the putative connections of the ␤, ␥, and ␦ isoforms to human cancer are much less explored. No somatic mutations of the genes encoding these isoforms have been reported (15) . However, increased expression of the ␤ and ␦ isoforms occurs in some colon and bladder tumors and in glioblastoma (17, 18) . Knockdown models suggest a role for the ␤ isoform in stimulating cell proliferation and invasive cell growth (19) . In acute myeloid leukemia, the ␦ isoform is important in the constitutive activation of Akt and controls cell proliferation (20) . The ␦ isoform also controls migration of breast cancer cells and may play a regulatory role in chemotaxis in tumor progression (21) . Recent reports suggest involvement of the ␥ isoform in tumor angiogenesis (22) and drug resistance of chronic myeloid leukemia cells (23) .
To gain more information on the potential role of the ␤, ␥, and ␦ isoforms of p110 in cancer, we have studied their ability to induce oncogenic transformation in cell culture. All three isoforms induce foci of transformed cells when overexpressed in chicken embryo fibroblasts (CEF). Kinase activity is essential for transformation. The isoforms differ, however, in their requirements for upstream activators and in their ability to stimulate downstream signaling cascades.
Results
The p110␤, -␥, and -␦ Isoforms of Class I PI3K Induce Oncogenic Transformation in Cell Culture. The ␤, ␥, and ␦ isoforms of p110 were expressed with the avian retroviral vector replicationcompetent avian leukosis virus with splice acceptor (RCAS) in chicken embryo fibroblasts. All three isoforms induced the formation of transformed cell foci within 10 days (Fig. 1) . These foci were particularly distinct in monolayer cultures expressing the ␥ or ␦ isoforms. The foci consisted of multiple layers of densely packed cells that contrasted sharply against the background of normal cells. The ␤ isoform induced less distinct foci with fewer cell layers in each focus. The efficiency of transformation as measured by focus forming units per ng of DNA was 0.044 for the p110␣ isoform, 0.9 for the ␤ isoform, 4.4 for the ␦ isoform, and 1.0 for the ␥ isoform. The fusion of a myristylation signal to the N terminus of the p110 isoforms enhanced oncogenic transforming ability. This enhancement was less pronounced with the ␥ and ␦ isoforms, which are potent transformers even without the added myristylation signal. In contrast, the transforming activity of the ␤ isoform was greatly enhanced upon fusion to a myristylation signal. The average focus forming activity per ng of DNA of the myristylated isoforms was 6.9 for the ␣ isoform, 4.3 for the ␤ isoform, 7.3 for the ␦ isoform, and 1.9 for the ␥ isoform. These data show that in contrast to p110␣, which in its wild-type version is not oncogenic, the ␤, ␥, and ␦ isoforms have an inherent oncogenic potential that is revealed by overexpression.
Oncogenic Transformation by p110 Isoforms Requires Kinase Activity.
PI3Ks are primarily lipid kinases that control diverse cellular processes by generating second messenger molecules, including phosphatidylinositol 3,4,5-trisphosphate (1, 2). However, PI3Ks also possess inherent protein kinase activity that can lead to autophosphorylation and phosphorylation of diverse target proteins (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . To determine the enzymatic activities required for oncogenic transformation, we generated kinase-inactive mutations and determined their transforming activity. The D910A mutation, which alters the aspartate residue located in the activation loop of the enzyme to an alanine, has been previously characterized in the ␦ isoform as a kinase-inactive mutant (36) . The ␦ isoform harboring this mutation was not able to induce focus formation, suggesting that intact kinase activity is required for transformation (Fig. 2) . The D910A mutation has not been studied in other isoforms, but the amino acid residue corresponding to D910 in p110␦ and its surrounding sequences are highly conserved in all isoforms of p110. We introduced this mutation in the ␥ isoform (D964A) and in the highly oncogenic mutant isoform p110␣ H1047R (D933A), and we observed a complete inhibition of transforming activity. Similar to the D964A mutation, the K832R mutation, which has been previously characterized in the ␥ isoform to be kinase-inactive (27) , completely blocked the transforming activity of p110␥. These results suggest a requirement for intact kinase activity of the p110 isoforms in the cellular transformation process.
We also tested a mutant that has lost lipid kinase activity but retains protein kinase activity. This lipid kinase-deficient p110 has previously been engineered and characterized in the ␣ and ␥ isoforms by substituting the conserved catalytic core sequence with the corresponding sequence of the target of rapamycin (TOR) (37, 38) . TOR belongs to the PI3K-related kinases; it has protein but not lipid kinase activity (39, 40) . The mutant p110␥ with only protein kinase activity failed to induce cellular transformation (Fig. 2) . The transforming activity of the oncogenic H1047R mutant of p110␣ isoform was also completely abrogated by this lipid kinase-inactive mutation. These data show that lipid kinase activity is essential for oncogenic transformation and that protein kinase alone is insufficient.
The ␦ Isoform of p110 Constitutively Activates the Akt Signaling Cascade. We have previously shown that oncogenic versions of p110␣ induce a constitutive activation of the Akt pathway (41, 42) . Here, we investigated downstream signaling of the p110␤, -␥, and -␦ isoforms. Chicken embryo fibroblasts transformed by these isoforms and positive and negative controls were examined by Western analysis with antibodies directed against Akt, phospho-Akt (Ser-473), p70 S6 kinase (S6K), and phospho-S6K (Thr-389) (Fig. 3A) . Even under serum-starved conditions, cells expressing p110␦ showed strong activation of the Akt pathway. The elevated levels of phospho-Akt and phospho-S6K present in p110␦-expressing cells were comparable to those detected in cells producing the oncogenic H1047R mutant of p110␣. In contrast, serum-starved cells expressing the ␤ or ␥ isoforms of p110 did not show constitutive activation of Akt. Only when cells were grown in the presence of 3% serum could activation of Akt by p110␥ be detected (Fig. 3B) . The p110␥ mutant lacking total kinase activity or lipid kinase activity failed to induce an increase in the phosphorylation level of Akt. This correlation between transforming activity and activation of Akt suggests that p110␥-induced cellular transformation depends on Akt. Kinase activity is required for transformation induced by the H1047R mutant of p110␣ and by wild-type p110␦ or p110␥. CEF on 10-cm plates were transfected with RCAS vectors encoding wild-type, lipid, and protein kinasenegative mutants, and mutants that are lipid kinase negative only. The p110␥-R1076H mutant, which carries the histidine residue corresponding to H1047 in the nononcogenic wild-type p110␣, is included as additional control. The R1076H mutation does not affect the native oncogenic potential of p110␥.
Binding to Ras Is Essential for Transformation by p110␤ and p110␥.
The four isoforms of p110 have Ras-binding domains in the N-terminal portion of their sequence. Previous studies have shown that a point mutation in this region, K227E, blocks the interaction of p110␣ with Ras and the ability of Ras to activate PI3K (43) . This mutation, when introduced into the myristylated form of p110␣ (41) , or into one of the oncogenic mutations of p110␣, had no effect on the transforming potential of the protein (Fig. 4) . The lysine residue that corresponds to K227 of the ␣ isoform is highly conserved in other p110 isoforms. Earlier studies had shown that the corresponding point mutation in the ␥ isoform (K255E) also interferes with the interaction with Ras (37), and we generated that mutation in p110␥. In contrast to the ␣ isoform, the K255E-mutated p110␥ was significantly compromised in its oncogenic potential (Fig. 4) . Similarly, the transforming activity of the ␤ isoform was inhibited when the corresponding mutation (K230E) was introduced in p110␤. The transforming potential of p110␦, however, was not affected by this mutation (K223E). These data suggest that the oncogenic activity of p110␤ and p110␥ depends on upstream input from Ras, but for p110␣ and p110␦ such input is not essential for transformation.
Inhibitory Effects of Rapamycin on Oncogenic Transformation Induced
by p110 Isoforms. We have previously shown that the transformation induced by oncogenic forms of p110␣ is mediated by TOR and can be effectively blocked by rapamycin, a specific inhibitor of TOR (42, 44) . To determine whether the oncogenicity induced by other members of class I PI3K is also TORdependent, the effect of rapamycin on the transforming activity of p110␤, -␦, and -␥ was investigated (Fig. 5) . Focus formation by the H1047R mutant of p110␣ was strongly inhibited at the concentration of 1 ng͞ml of rapamycin, as previously reported (42) . Similarly, cellular transformation induced by other isoforms of class I PI3K was substantially inhibited by the same concentration of rapamycin. However, rapamycin had no effect on the transforming activity of the v-Jun oncoprotein. These results suggest that the oncogenic signal of p110␤, p110␥, and p110␦ is mediated by a TOR-dependent process.
Discussion
Overexpression of the wild-type catalytic subunits p110␤, -␥, or -␦ of class I PI3K is sufficient to induce an oncogenic phenotype in cultured cells. In contrast, wild-type p110␣ lacks this transforming potential but can acquire it by point mutations or by the addition of a myristylation or farnesylation signal (41, 42) . The potential role of the non-␣ isoforms of class I PI3K in cancer has not been fully explored. However, there are reports of elevated expression of p110␤ and p110␦ in various human cancers (17, 18) . In contrast to the prevalence of p110␣ mutations detected in various tumor types, there have been no reports of cancerspecific mutations in p110␤, -␥, or -␦ (15). It is possible that this absence of mutations in the non-␣ isoforms reflects their oncogenic potential as wild-type proteins. Differential expression of wild-type p110␤, -␥, or -␦ could conceivably make a contribution to the oncogenic phenotype of the cancer cell. . CEF that were transfected with empty RCAS vector, wild-type p110␣ (human), the H1047R mutant of p110␣, or wild-type p110␤, p110␦, p110␥, or Vps34p (class III PI3K) were serum starved for 42 h. Cells were then lysed, and the proteins were separated on a 3-8% gradient SDS͞polyacrylamide gel. The transferred blot was probed with antibodies as indicated. (B) Activation of Akt in wild-type and mutant p110␥-expressing cells in media containing 3% serum. CEF that were transfected with wild-type, kinase-inactive mutants (D964A and lipid-kinase inactive), or Ras binding-inactive mutant (K255E) of p110␥ were overlaid with nutrient agar containing 3% serum for 10 days. The agar was then removed, the cells were harvested and lysed, and the proteins were analyzed as described above. Reexamining expression profiles of various cancers for possible up-regulation of non-␣ isoforms at the RNA and protein levels appears worthwhile.
The reasons for the oncogenic potential of the non-␣ isoforms of p110 are not known. Some mutated residues that are linked to a gain of function in p110␣ are found in wild-type non-␣ isoforms. For instance, the H1047R mutation of p110␣ is highly oncogenic; the p110␥ wild-type protein carries an arginine residue at the corresponding site (R1076). Yet the arginine to histidine mutation at this site in p110␥ does not affect oncogenicity (Fig. 2) . The N345K mutation in the C2 domain also makes p110␣ oncogenic (M. Gymnopoulos and P.K.V., unpublished data). The corresponding residue of the wild-type p110␤ (K342) and p110␦ (K332) already contains lysine at this site. The effect of mutating these residues in p110␤ and p110␦ to the corresponding asparagine residue of p110␣ remains to be determined. Introducing the cancer-specific mutations of p110␣ into the non-␣ isoforms may provide information on oncogenic mechanisms.
The oncogenicity of all isoforms of class I p110 depends on kinase activity. For mutant p110␣ and wild-type p110␥, lipid kinase is essential (Fig. 2) . Protein kinase may also be required but is not sufficient. For p110␤ and -␦, the relative roles of lipid versus protein kinase activities remain to be investigated. However, the tumor-suppressive effect of the lipid phosphatase PTEN strongly argues in favor of a dominant, if not exclusive, role of lipid kinase activities in the oncogenic transformation induced by p110 isoforms.
The requirements for upstream and downstream signaling in the transformation process induced by the p110 isoforms are in accord with published literature. These requirements divide the isoforms into two groups: one consisting of p110␣ and -␦, the other encompassing p110␤ and -␥. Both p110␣ and -␦ are linked to upstream receptor tyrosine kinases (reviewed in refs. 45 and 46) . Although p110␣ and -␦ have Ras-binding domains and can bind Ras, a mutation that abolishes Ras binding of oncogenic p110␣ does not interfere with transformation. The analogous mutation in p110␦ also retains transforming potential, but the effect of this mutation on Ras binding remains to be determined (Fig. 4) . Cancer-specific mutations of p110␣ and the wild-type protein p110␦ are strong stimulators of Akt signaling, which is activated constitutively under serum-starved conditions. In contrast to the ␣ and ␦ isoforms, upstream signaling to the ␥ isoform originates with G protein-coupled receptors (2, 7, 8) . The ␤ isoform can be activated by G protein-coupled receptors and by receptor tyrosine kinases (9) (10) (11) 45) . The ␥ isoform depends on interaction with Ras for oncogenic transformation, and the same appears to be true of p110␤, although additional data on Ras binding are needed to confirm this conclusion (Fig. 4) . The upstream signaling requirements of the p110␤ and -␥ isoforms are therefore distinct from those of the ␣ and ␦ isoforms. The ␤ and ␥ isoforms are also set apart by their effect on Akt. Under conditions of serum starvation, they do not induce a detectable activation of Akt (Fig. 3A) . These results are consistent with the recent findings showing that the wild-type p110␤ by itself does not induce activation of Akt in human mammary epithelial cells under serum-starved conditions (47) . However, adding a myristylation signal to the N terminus of p110␤ results in a constitutive, serum-independent activation of Akt (47, 48) . Similarly, the myristylated form of p110␥ also induces constitutive activation of Akt in Rat1 fibroblasts (48) , but the stimulating effect of the wild-type p110␥ on Akt is revealed only in the presence of serum (Fig. 3B) , and that effect is weak compared to that of the ␣ and ␦ isoforms. Yet oncogenic transformation by all four isoforms of class I PI3K is highly sensitive to rapamycin (Fig. 5) . The Akt-TOR axis is therefore an essential and common feature of the transforming signal emanating from the isoforms of p110.
The relative enzymatic activity of p110␣ is higher than that of other isoforms (49, 50) , suggesting that the inability of the wild type p110␣ to induce transformation is not due to low specific activity. Western analyses suggest that the non-␣ isoforms of p110 are expressed at higher levels than p110␣, assuming that the sensitivities of isoform detection by the different antibodies are roughly comparable (Fig. 3) . Overexpression of p110␣ but not of p110␤ may be toxic (51) , and the inability of wild-type p110␣ to induce oncogenic transformation could be attributed to low levels of expression.
Expression of p110␣, -␤, and -␦ (class IA PI3K) depends on the availability of the corresponding regulatory subunits, which may stabilize the catalytic subunits (49, 52, 53) . In contrast, p110␥ of class IB PI3K is stable as a monomer without its regulatory subunit p101 (54, 55) . Although we have not cotransfected the regulatory subunits with p110 isoforms, stable overexpression of p110␤, -␦, and -␥ was achieved (Fig. 3) . This observation suggests that endogenous p85 expressed in CEF may function as a stabilizing factor (Fig. 3) . Expression of a particular p110 isoform of class IA tends to affect the expression levels of other isoforms that share the same regulatory subunit. For example, the endogenous levels of p110␣ are down-regulated in cells overexpressing the ␤ or ␦ isoform. Expression of the ␦ isoform also leads to reduced endogenous levels of p110␤ (Fig.  3) . Overexpression of a particular p110 isoform may therefore titrate the corresponding regulatory subunit, limiting the availability to other isoforms and, thus, cause down-regulation.
The unexpected oncogenic potential of the non-␣ isoforms of p110 places these proteins in the same category with oncoproteins like Myc, which also induces oncogenic transformation as a wild-type protein if overexpressed (56) (57) (58) (59) . The extent to which the non-␣ isoforms of p110 contribute to human cancer needs to be investigated in future studies.
Materials and Methods
Cell Culture and Transformation Assays. Primary cultures of CEF were prepared from White Leghorn embryos obtained from Charles River Breeding Laboratories (Preston, CT). For transformation assays, DNA was transfected into CEF by using either the Lipofectamine reagent (Invitrogen, Carlsbad, CA) or the DMSO͞Polybrene method (60) . After incubation of cells under nutrient overlay, foci of transformed cells were counted on day 10 after transfection. Assays with infectious retroviral vectors were performed as described in ref. 13 and 61 . Transfected or infected cells were fed every other day with nutrient agar and then stained with crystal violet. For serum starvation, subconfluent cultures were maintained in Ham's F-10 medium with 0.5% FCS and 0.1% chicken serum. After 40-44 h, the cells were harvested for protein analysis.
Plasmid Construction. Wild-type and myristylated chicken p110␣ expression constructs were described in ref. 41 . The human wild-type p110␣ expression construct was generated by PCR amplification of the original cDNA clone DKFZp686D20244 (RZPD, Berlin) by using the primers Hu-␣-koz-F͞Hu-␣-rev (see Table 1 , which is published as supporting information on the PNAS web site, for the primer sequences). The PCR product was MluI-and ClaI-digested and cloned into MluI and ClaI cloning sites of pBSFI adaptor plasmid (62) . To generate human wildtype p110␤, p110␦, and p110␥ constructs, the same cloning procedures were used with the following exceptions: p110␤ was PCR amplified from the ''pBS-SK(ϩ)-hump110␤'' plasmid (B.V., unpublished data) by using the primers ␤-koz-for͞␤-rev and digested with EcoRI and HindIII. p110␦ was PCR-amplified from the ''pMT2SM-oligoϩhp110␦WTnotag3UTR plasmid'' (B.V., unpublished data) by using the primers ␦-koz-for͞␦-rev and digested with BamHI and ClaI. p110␥ was PCR-amplified from the ''pcDNA3-p110␥-VSV'' plasmid (63), a generous gift from Reinhard Wetzker (Friedrich Schiller-University, Jena, Germany), with the primers ␥-koz-for͞␥-rev and digested with BamHI and MluI. Digested PCR products were cloned into corresponding sites of the pBSFI cloning vector, and then subcloned into the avian retroviral vector RCAS.Sfi, a modified version of RCAS (62) .
For myristylated p110 constructs, similar cloning procedures were used with the following modifications: p110␤ was PCRamplified by using primers ␤-5Ј-Mlu and ␤-3Ј-Hind and cloned into MluI and HindIII sites of the Myr-pBSFI vector, which contains the amino-terminal 14 amino acids of c-Src. The Myr-pBSFI plasmid was previously constructed by cloning the annealed oligonucleotide strands (Myr-5ЈB and Myr-3ЈM) into the BamHI and MluI sites of the pBSFI vector. p110␦ and p110␥ were PCR-amplified by using primers ␦-5Ј-Mlu͞␦-3Ј-Cla and ␥-5Ј-Mlu͞␥-3Ј-Sal, respectively, and cloned into MluI, ClaI and MluI, SalI sites of the Myr-pBSFI vector.
The following point mutations were generated by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) with the indicated sets of primers: human p110␣ H1047R (primers Hu-␣-H1047R1͞Hu-␣-H1047R2), p110␣ H1047R͞ K227E (primers ␣H1047R-K227E1͞␣H1047R-K227E2), p110␣ H1047R͞D933A (primers ␣H1047R-D933A1͞␣H1047R-D933A2), p110␤-K230E (primers ␤-K230E1͞␤-K230E2); p110␦-K223E (primers ␦-K223E1͞␦-K223E2), p110␦-D910A (primers ␦-D910A1͞␦-D910A 2); p110␥-K255E(primers ␥-K255E1͞␥-K255E2), p110␥-D964A (primers ␥-D964A1͞␥-D964A2), and p110␥-K832R(primers ␥-K832R1͞␥-K832R2); p110␥-R1076H (primers ␥-R1076H1͞␥-R1076H2). Lipid kinase-inactive mutants of p110␣H1047R and p110␥ were constructed as described in refs. 37 and 38.
Western Analysis. Western blotting was performed as described in refs. 41 and 42. In addition to previously described antibodies, anti-phospho-Akt (T308) antibody and anti-p85 antibody were obtained from Cell Signaling Technology (Beverly, MA), antip110␤ antibody (S-19) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and VSV-G polyclonal antibody (PRB-192P) was purchased from Covance Research Products (Berkeley, CA) to detect VSV-tagged p110␥ proteins. Antip110␦ antibody has been described in ref. 3. We thank Dr. Andreas Bader for helpful discussion with the manuscript, Lynn Hamaguchi-Ueno for assistance in cell culture, and Dr. Marco Gymnopoulos for permission to mention unpublished observations. This work is supported by grants from the National Cancer Institute and the Ludwig Institute for Cancer Research. This paper is manuscript no. 17722-MEM of The Scripps Research Institute.
